Key Principles and Recommended Regimens for First-line Antiretroviral Therapy
Considerations for Choosing Boosted PI vs INSTI-Based Therapy
When choosing between INSTI-based and boosted PI–based therapy, the following considerations might be taken into account:
- Dosing
- There is now 1 boosted PI–based coformulated single-tablet regimen, cobicistat/darunavir/emtricitabine/tenofovir AF. The boosted PIs atazanavir/cobicistat and cobicistat/darunavir are also coformulated, but the NRTI pair must be given separately
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content